Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EUSA Pharma (UK) Ltd.

http://www.eusapharma.com/

Latest From EUSA Pharma (UK) Ltd.

Recordati Expands Into Rare Cancer Space With EUSA Pharma Buy

The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.

Companies Deals

Emerging Biopharma’s Next First Launch Market: China?

Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states. 

China Commercial

Keeping Track: US FDA Approval Of Jazz Rylaze Addresses Shortage; MediWound, Cyclopharm Receive CRLs

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Approvals

China At Global Rare Disease Crossroads: CANbridge CEO

The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.

China Rare Diseases
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register